Rivastigmine Transdermal System Patch, Extended Release
Product Images NDC 72162-1610

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Rivastigmine Transdermal System (NDC 72162-1610). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl721621610)

Label for Rivastigmine Transdermal System 13.3 mg/24 hours patch. The label includes the NDC 72162-1610-3 and states each 15 cm2 patch contains 27 mg rivastigmine base, providing 13.3 mg over 24 hours. It is relabeled by Bryant Ranch Prepack, Inc. and manufactured by AdhexPharma. The package contains 30 systems with directions and storage instructions.*

FDA Label Image

Chemical Structure (Rivastigmine 01)

Chemical structure diagram of Rivastigmine, showing its molecular arrangement with labeled functional groups and bonds.*

FDA Label Image

Figure 1 (Rivastigmine 02)

An illustration diagram showing a cross-sectional view of a multilayer patch with four distinct horizontal layers. The diagram highlights two areas labeled 'Dimple' with arrows pointing to indented sections on the sides of the bottom layer of the patch.*

FDA Label Image

Figure 2 (Rivastigmine 03)

A line graph showing the plasma concentration of Rivastigmine (ng/mL) over time (hours) for three different dosages of Rivastigmine Transdermal System patch: 13.3 mg/24 hours, 9.5 mg/24 hours, and 4.6 mg/24 hours. The graph includes error bars and indicates sample size for each dosage group.*

FDA Label Image

Figure 3 (Rivastigmine 04)

A line graph depicting least square mean changes from baseline in ADAS-cog ratings over 24 weeks of treatment. The graph compares four groups: 17.4 mg/24 hours, 9.5 mg/24 hours, capsules 6 mg BID, and placebo, showing clinical improvement or decline over time with weeks on the x-axis and change in ADAS-cog rating on the y-axis.*

FDA Label Image

Figure 4 (Rivastigmine 05)

A bar graph showing the percentage of patients by ADCS-CGIC rating categories for four treatment groups: 17.4 mg/24 hours, 9.5 mg/24 hours, capsules 6 mg BID, and placebo. Ratings range from Markedly Improved to Markedly Worse, with the highest percentages in the No Change category for all groups.*

FDA Label Image

Figure 5 (Rivastigmine 06)

A line graph depicting the ADCS-ADL change from baseline (LS means SEM) over 48 weeks of treatment with Rivastigmine Transdermal System at doses of 13.3 mg/24hr and 9.5 mg/24hr. The x-axis shows weeks of treatment, and the y-axis indicates clinical improvement to decline. Data points with error bars reflect trends in clinical outcomes over time for both dosage strengths.*

FDA Label Image

Figure 6 (Rivastigmine 07)

A line graph comparing ADAS-Cog change from baseline over 48 weeks of treatment for rivastigmine transdermal systems at 13.3 mg/24hr and 9.5 mg/24hr strengths. The vertical axis measures ADAS-Cog change with clinical improvement upward and clinical decline downward. The graph shows data points with error bars for both dosages over time.*

FDA Label Image

Figure 7 (Rivastigmine 08)

A line graph comparing the least squares mean change in clinical response over 24 weeks of treatment between two Rivastigmine Transdermal System patch sizes: 15 cm² and 5 cm². The y-axis shows LS mean change with standard error, from clinical improvement to clinical decline, with data points at 0, 8, 16, and 24 weeks on the x-axis. Statistical values and p-values are indicated for comparisons between groups.*

FDA Label Image

Figure 8 (Rivastigmine 09)

A line graph displaying least squares (LS) mean change from baseline over 24 weeks for Rivastigmine Transdermal System. The x-axis shows weeks of treatment (0, 8, 16, 24), and the y-axis displays LS mean change with standard error (ranging from -8 to 3). Two dose sizes are compared: 15 cm² and 5 cm², with LS mean differences and p-values annotated at weeks 8, 16, and 24. The graph includes vertical labels indicating clinical improvement and clinical decline.*

FDA Label Image

Figure A (Rivastigmine 10)

Illustration depicting the Rivastigmine Transdermal System, showing the patch with protective liners, adhesive containing the medicine, and outside backing. It also includes the pouch packaging labeled with the product name and usage instructions.*

FDA Label Image

Figure B (Rivastigmine 11)

Diagram showing recommended application sites for a patch on the body. It includes shaded areas on the left or right upper arm, left or right side of the chest, left or right upper back, and left or right lower back, demonstrating possible locations for transdermal patch placement.*

FDA Label Image

Figure C (Rivastigmine 12)

An instructional illustration showing a hand holding a Rivastigmine Transdermal System patch package while scissors are positioned to cut open the package. This depicts how to open the patch packaging for use.*

FDA Label Image

Figure D (Rivastigmine 13)

An instructional illustration showing hands peeling protective liners from the sticky surface of a patch, demonstrating how to prepare a transdermal patch for application.*

FDA Label Image

Figure E (Rivastigmine 14)

An instructional illustration showing the application of a transdermal patch on the upper back of a person. One hand is positioning the patch on the back while the other hand appears to be peeling off the backing, demonstrating how to apply the Rivastigmine transdermal system patch.*

FDA Label Image

Figure F (Rivastigmine 15)

An instructional illustration showing a person applying a transdermal patch to the upper back between the shoulder blades. The image depicts the proper placement of a patch on the skin.*

FDA Label Image

Figure G (Rivastigmine 16)

An instructional illustration showing a person applying a Rivastigmine Transdermal System patch to their upper chest. The image depicts one hand holding the patch and the other hand smoothing it onto the skin, indicating the correct placement and application method for the transdermal patch.*

FDA Label Image

Figure H (Rivastigmine 17)

An instructional illustration showing three steps for proper disposal of the Rivastigmine Transdermal System patch: folding the sticky sides together, sliding the folded patch into an empty pouch, and placing the pouch into the trash while keeping it away from children and pets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.